<code id='15F4208BE4'></code><style id='15F4208BE4'></style>
    • <acronym id='15F4208BE4'></acronym>
      <center id='15F4208BE4'><center id='15F4208BE4'><tfoot id='15F4208BE4'></tfoot></center><abbr id='15F4208BE4'><dir id='15F4208BE4'><tfoot id='15F4208BE4'></tfoot><noframes id='15F4208BE4'>

    • <optgroup id='15F4208BE4'><strike id='15F4208BE4'><sup id='15F4208BE4'></sup></strike><code id='15F4208BE4'></code></optgroup>
        1. <b id='15F4208BE4'><label id='15F4208BE4'><select id='15F4208BE4'><dt id='15F4208BE4'><span id='15F4208BE4'></span></dt></select></label></b><u id='15F4208BE4'></u>
          <i id='15F4208BE4'><strike id='15F4208BE4'><tt id='15F4208BE4'><pre id='15F4208BE4'></pre></tt></strike></i>

          fashion

          fashion

          author:hotspot    Page View:489
          Johnson & Johnson sign
          MARK RALSTON/AFP via Getty Images

          WASHINGTON — Pharmaceutical giant Johnson & Johnson on Tuesday became the third drugmaker to sue the Biden administration over its new Medicare drug price negotiation program.

          J&J joins a flurry of litigation challenging the Medicare drug price negotiation program, which is set to start this fall. Merck, Bristol Myers Squibb, the brand-drug lobby PhRMA, and the U.S. Chamber of Commerce have also filed suit. The negotiated prices would go into effect in 2026.

          advertisement

          The company argued that it is entitled to sue because its blockbuster blood thinner drug Xarelto may be up for negotiation in the first round of ten drugs Medicare will examine, but that list is not set to be announced officially until Sept. 1.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          leisure time

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          What it's like to live with paralysis for one psychologist
          What it's like to live with paralysis for one psychologist

          Photoillustration:CaseySheneryforSTATNikkiSaltzburgwasbornthreemonthsprematurewhileherparentswerevac

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          New Alzheimer's drugs heat up race for early detection blood tests

          MarionBerard/AFP/GettyImagesWiththeadventofdisease-modifyingAlzheimer’sdrugs,everyoneintheworldofAlz